"We invest to create delivery systems that better fit the needs of people," Cincotti says. Working with leading universities and with counterparts across the globe, IBSA scientists and engineers optimise the use of active ingredients in developing distinct pharmaceutical forms. The company has accomplished groundbreaking strides in the implementation of new technologies and molecules to develop products for pain and inflammation, endocrinology, dermatology, urology, respiratory, rheumatology and fertility - its core therapeutic areas.

In the area of pain and inflammation, IBSA was the first company to develop transdermal patches for drug delivery, 25 years ago. Based on its own patented diclofenac molecule, which can penetrate the skin, IBSA's anti-inflammatory Flector patch can deliver painkillers topically and without negative side effects on the body.

IBSA also patented the first softgel capsules for thyroid diseases. The only breakthrough drug development in the past 40 years in the field of endocrinology, IBSA's Tirosint softgel capsules are an improved and safer means of delivering hormones to patients. IBSA manufactures the softgel capsules using its patented PEARLtec encapsulation system, which guarantees precise formulations and ensures batch-to-batch consistency.

Recognising the social and psychological factors affecting the area of human reproduction, IBSA addresses the complex clinical issue of infertility through various assisted reproductive technologies. Its research advancements in administering hormones via a watery solution resulted in a less painful alternative to intramuscular injections or vaginal applications. 

Marketed as Fostimon, the subcutaneously administered drug is widely distributed in Italy, France and the United States. It is also sold in more than 300 infertility centres on the mainland and in Hong Kong.

Following Fostimon's success on the mainland, the company is securing registration approvals to manufacture and distribute other proprietary products in the country. With the Asian region gradually emerging as the centre of gravity for pharmaceutical manufacturing, IBSA is building a second factory on the mainland to expand its diagnostics business. It welcomes partnerships with established companies in the region to scale up distribution and diversification activities.

"We are proud and happy when we make a product in our own factory or open brand-new factories," Cincotti says. "Our facilities are actually not factories, but pieces of our hearts."

IBSA continues to undertake market research and clinical trials on the mainland and in its production centres in Switzerland and Italy to stay at the forefront of innovation for patients and markets worldwide.

"What we do is very special," Cincotti says. "We offer Swiss direction, quality and systems. Regardless of location, you will find the same ideas, quality management and precise strategy in all our centres."